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Abstract: Novel advanced spray-dried and co-spray-dried inhalable lung surfactant-mimic
phospholipid and poly(ethylene glycol) (PEG)ylated lipopolymers as microparticulate/
nanoparticulate dry powders of biodegradable biocompatible lipopolymers were rationally
formulated via an organic solution advanced spray-drying process in closed mode using
various phospholipid formulations and rationally chosen spray-drying pump rates. Ratios of
dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine PEG (DPPEPEG) with varying PEG lengths were mixed in a dilute methanol solution. Scanning electron
microscopy images showed the smooth, spherical particle morphology of the inhalable particles.
The size of the particles was statistically analyzed using the scanning electron micrographs and
SigmaScan® software and were determined to be 600 nm to 1.2 µm in diameter, which is optimal
for deep-lung alveolar penetration. Differential scanning calorimetry (DSC) and powder X-ray
diffraction (PXRD) were performed to analyze solid-state transitions and long-range molecular
order, respectively, and allowed for the confirmation of the presence of phospholipid bilayers
in the solid state of the particles. The residual water content of the particles was very low, as
quantified analytically via Karl Fischer titration. The composition of the particles was confirmed
using attenuated total-reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy and confocal Raman microscopy (CRM), and chemical imaging confirmed the chemical homogeneity
of the particles. The dry powder aerosol dispersion properties were evaluated using the Next
Generation Impactor™ (NGI™) coupled with the HandiHaler® dry powder inhaler device, where
the mass median aerodynamic diameter from 2.6 to 4.3 µm with excellent aerosol dispersion
performance, as exemplified by high values of emitted dose, fine particle fraction, and respirable
fraction. Overall, it was determined that the pump rates defined in the spray-drying process had
a significant effect on the solid-state particle properties and that a higher pump rate produced
the most optimal system. Advanced dry powder inhalers of inhalable lipopolymers for targeted
dry powder inhalation delivery were successfully achieved.
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Introduction
The lung is an ideal target for targeted drug delivery, due to
the potential to deliver therapeutic aerosols, which allows
for uniform drug distribution, the avoidance of first-pass
metabolism, a rapid onset of action, and high drug concentrations within the lung.1–4 Furthermore, the presence of drug
at the site of pathology with minimal systemic absorption
leads to decreased side effects.5 Inhalation aerosols enable
therapeutic effects to be achieved at much lower drug doses
compared to other routes of administration offering inherently
longer residence time in the lungs, which can reduce dosing frequency and increase patient compliance.2,5–8 Aerosol
formulations have been investigated for many pulmonary
diseases including cystic fibrosis, asthma, chronic obstructive
pulmonary disease, lung infections, and lung cancer.9–15 Inhalation aerosols for the treatment of pulmonary diseases date
back to ancient times7,16 and many inhalation products exist,
of which dry powder inhalers (DPIs) are the fastest-growing
segment. DPI formulations offer many advantages, including
storing the drug in a dry state, leading to long-term stability,17
the ability to encapsulate various types of therapeutics,18 and
the ease of DPI implementation.6,19
Dry powder aerosol formulations of nanoparticles and
microparticles are of significant interest for direct lung
delivery.14,20,21 In particular, the use of phospholipids as multifunctional biocompatible biodegradable excipients for the
delivery of therapeutics to the lungs is an attractive option.22
Phospholipids have been shown to improve particle migration to the lung periphery, owing to the reduction in surface
tension provided by these biosurfactants,23–27 especially to
poorly water-soluble drugs. The use of phospholipids in
pulmonary delivery is logical in that lung surfactant is a
mixture primarily comprised of phospholipids and smaller
amounts of lung surfactant-specific surface-active proteins.
In particular, dipalmitoylphosphatidylcholine (DPPC) is the
primary phospholipid component in lung surfactant, making
up 55%–60% of the mixture. DPPC serves a vital role in
reducing the work of breathing, and pulmonary immunity
modulation, and is used in several successful lung surfactant
replacement nanopharmaceutical products.14 In addition to
DPPC being an innate component of the lung, it offers advantages in drug delivery owing to its transition temperature.
Transition temperatures of phospholipids are highly
dependent on the saturation and length of carbon chains and
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DPPC (a diacyl 16-saturated carbon chain phospholipid) has
a transition temperature of 41°C (above physiological body
temperature of 37°C) when fully hydrated, which may offer
controlled drug release.1,14,28
The use of poly(ethylene glycol) (PEG)-based liposomal
formulations has been motivated by the advantage of having biocompatible self-assembled drug-delivery systems
that can evade the recognition and uptake by cells in the
immune system while prolonging the residence time of the
liposomes and providing sustained drug release.14,29–32 In addition, PEG has been recently demonstrated to have inherent
mucus-penetrating properties.33 Unlike other types of inhaled
particles, the fate of phospholipid-based particles can have
a similar fate to native lipids. The processing, uptake, and
recycling of phospholipid particles occurs through the same
mechanism as endogenous surfactant via alveolar type II
pneumocytes.29 In addition, there are successful nanopharmaceutical products containing PEGylated phospholipid
for intravenous administration, as it is an FDA-approved
excipient.14,20,21,32 Sterically stabilized nanomicelles comprised of PEGylated phospholipids with encapsulated drug
for the treatment of acute lung injury by the intravenous route
have been reported.34,35
The spray-drying method is an advanced high-throughput
pharmaceutical manufacturing process that is used to efficiently produce and tailor respirable particles in the solid
state.2,8,14,36 Spray-drying has been used in the microencapsulation of bioactive molecules, as well as in the preparation of
drug-delivery systems composed of a large variety of biodegradable polymers and excipients.37–39 It has also been used
as a scalable method in the bulk preparation of drug–lipid
mixtures.37,40,41 The unique features and tunable parameters
of spray-drying allow for the precise tuning of the particle
properties as a result of rational design and engineering. The
use of an organic solvent allows for much lower moisture
content and smaller particle size (down to 400 nm). This
along with the inherently lower surface tension of the solvent
combined with dilute solution concentrations allows particle
formulation in the solid state in the inhalable range.
The rational design and development of inhalable lung
surfactant-mimic DPPC and PEGylated phospholipid with
varying PEG chain length as respirable microparticles
and nanoparticles as one-component spray-dried (SD)
and two-component co-SD DPIs for targeted pulmonary
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nanomedicine are reported for the first time in this comprehensive and systematic study. The novel aspects of this
study include organic solution advanced spray-drying in
closed mode, the rational design and formulation of lung
surfactant-mimic DPPC together with dipalmitoylphosphatidylethanolamine (DPPE)-PEG of varying PEG chain
lengths as respirable dry powder particles, optimization
for targeted pulmonary nanomedicine delivery as inhalable microparticles and nanoparticles in the solid state, and
systematic comprehensive analyses. The rational design
and optimization of these advanced dry powder inhalation
aerosol nanomedicine formulations as aerosolized lung
surfactant-mimic and lipopolymers as DPIs is important
to allow for better understanding of the physicochemical
properties and interactions of these particles formulated by
advanced organic spray-drying and co-spray-drying processes in closed mode. To the authors’ knowledge, this is the
first report on a comprehensive and systematic study on the
advanced formulation and characteristics of various combinations of DPPC and PEGylated phospholipids comprised of
various PEG lengths for targeted pulmonary nanomedicine
as inhaled dry powder aerosols.

Methanol (high-performance liquid chromatography [HPLC]
grade, American Chemical Society [ACS]-certified and
chloroform [HPLC grade, ACS certified]) was obtained
from Fisher Scientific (Pittsburgh, PA). Hydranal-Coulomat
AD was from Sigma-Aldrich (St Louis, MO). Ultrahighpurity (UHP) dry nitrogen gas was from Scott-Gross
(Lexington, KY). All materials were used as stored in the
freezer at −23°C and used as received.

Organic solution advanced spray-drying
and co-spray-drying in closed mode
from dilute solution
Advanced spray-drying of single-component DPPC
and PEGylated phospholipids and co-spray drying of
DPPC:PEGylated two-component systems from dilute
organic solution was performed with a B-290 Büchi Mini
Spray Dryer coupled with a B-295 Inert Loop and highperformance cyclone (all from Büchi Labortechnik, Flawil,
Switzerland) in closed mode using UHP dry nitrogen gas
as the atomizing gas. The feed solutions were prepared by
dissolving various amounts of DPPC and/or DPPE-PEG in
methanol to form dilute organic solutions of 0.1% w/v. Based
on our previous organic solution advanced spray-drying
work,42 the following spray-drying conditions were used:
atomization gas flow rate of 600 L/hour, aspiration rate of
35 m3/hour, inlet temperature of 150°C (maintained in the first
spray-drying process), and three different pump rates, designated as “low P,” “med P,” and “high P” pump rates, which
corresponded to 3 mL/minute (10%), 15 mL/minute (50%),
and 30 mL/minute (100%), respectively. Table 1 shows the
various formulated particle systems and their corresponding
DPPC and DPPE-PEG amounts and types, pump rates, and
outlet temperatures (which represent the secondary drying

Materials and methods
Materials
Synthetic DPPC (molecular weight 734.039 g/mol, .99%
purity) and DPPE-PEG (molecular weights: 2749.391 g/mol,
3716.304 g/mol, and 5741.510 g/mol, which correspond
to 2000, 3000, and 5000 molecular weight PEG lengths
per compound; .99% purity) were obtained from Avanti
Polar Lipids (Alabaster, AL). Their corresponding chemical
structures are shown in Figure 1 (ChemSketch 12.01;
Advanced Chemistry Development, Toronto, Canada).
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Figure 1 Chemical structures of (A) dipalmitoylphosphatidylcholine and (B) dipalmitoylphosphatidylethanolamine methoxy-poly(ethylene glycol).
Notes: n = 45, 67, and 113 for 2000, 3000, and 5000 MW poly(ethylene glycol), respectively, where n denotes the number of ethylene glycol oligomers present.
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Table 1 Formulated spray-dried and co-spray-dried particle systems, their corresponding DPPC and/or DPPE-PEG amounts, and
spray-drying conditions where low P, medium P, and high P correspond to 10%, 50%, and 100% pump rates, respectively
System

DPPC (mol%)

DPPE-PEG
(mol% and PEG MW)

Pump rate
(mL/minute) (%)

Outlet T
(°C)

100 DPPC (low P)
100 DPPC (medium P)
100 DPPC (high P)
95 DPPC:5 DPPE-PEG2k (low P)
95 DPPC:5 DPPE-PEG2k (medium P)
95 DPPC:5 DPPE-PEG2k (high P)
95 DPPC:5 DPPE-PEG3k (low P)
95 DPPC:5 DPPE-PEG3k (medium P)
95 DPPC:5 DPPE-PEG3k (high P)
95 DPPC:5 DPPE-PEG5k (low P)
95 DPPC:5 DPPE-PEG5k (medium P)
95 DPPC:5 DPPE-PEG5k (high P)

100
100
100
95
95
95
95
95
95
95
95
95

0
0
0
5 (2k)
5 (2k)
5 (2k)
5 (3k)
5 (3k)
5 (3k)
5 (5k)
5 (5k)
5 (5k)

3 (10%)
15 (50%)
30 (100%)
3 (10%)
15 (50%)
30 (100%)
3 (10%)
15 (50%)
30 (100%)
3 (10%)
15 (50%)
30 (100%)

85
70
49
71
73
40
73
79
43
69
64
37

Abbreviations: DPPC, dipalmitoylphosphatidylcholine; DPPE, dipalmitoylphosphatidylethanolamine; PEG, poly(ethylene glycol).

process temperatures). The nozzle diameter (composed of
stainless steel) was 0.7 mm, and the spray-dried particles
were separated from the drying gas (UHP nitrogen) in
the high-performance cyclone and collected in a sample
collector. All SD and co-SD powders were stored in glass
vials sealed with parafilm in glass desiccators over Drierite
(Xenia, OH) desiccant in the freezer at −23°C under ambient pressure.

Scanning electron microscopy
for morphology and shape analysis
The shape and surface morphology of particles was
evaluated by scanning electron microscopy (SEM), using
a Hitachi S-4300 microscope (Tokyo, Japan). Samples
were placed on double-sided adhesive carbon tabs and
were adhered to aluminum stubs (TedPella, Redding, CA)
which were coated with a gold/palladium alloy thin film
using an Emscope SC400 sputter coating system at 20 µA
for 1 minute under argon gas. The electron beam with an
accelerating voltage of 5–10 kV was used at a working
distance of 13.3–15.3 mm. Images were captured at several
magnifications.

Particle sizing and size
distribution using SEM
The mean size, standard deviation, and size range of the particles were determined digitally using SigmaScan® 5.0 software
(Systat, San Jose, CA). Representative micrographs for each
particle sample at 5000× magnification were analyzed by
measuring the diameter of at least 100 particles per image
with the SigmaScan software.
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Powder X-ray diffraction
Using similar conditions previously reported by the authors,42
powder X-ray diffraction (PXRD) patterns of powder samples
were measured by a Rigaku Multiflex X-ray diffractometer
(The Woodlands, TX) with a slit-detector Cu Kα radiation
source (40 kV, 44 mA, and λ = 1.5406 Å). The scan range
was 5.0–50.0 2θ (°) with a scan rate of 2.0°/minute at ambient
temperature. The sample was placed on a horizontal quartz
glass sample holder plate.

Differential scanning calorimetry
Thermal analysis and phase-transition measurements were
carried out using a TA Q200 differential scanning calorimetry
(DSC) system (TA Instruments, New Castle, DE) equipped
with T-Zero ® technology and an automated computercontrolled RSC-90 cooling accessory. Using similar conditions previously reported by the authors,42 1–3 mg of powder
was weighed into hermetic anodized aluminum T-Zero® DSC
pans and were hermetically sealed with the T-Zero® hermetic
sealer. UHP dry nitrogen gas was used as the purging gas at
50 mL/minute. The heating range was 0°C–250°C at a heating
scan rate of 5.00°C/minute.

Karl Fischer coulometric titration
The water content of all powders was chemically quantified
by Karl Fisher (KF) coulometric titration, using similar conditions previously reported by the authors.42 The measurements
were performed with a 737 KF Coulometer coupled with 703
Ti Stand (Metrohm, Antwerp, Belgium). Approximately 5 mg
of powder was dissolved in a known volume of chloroform.
The sample solution was injected into the reaction cell that
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contained Hydranal KF reagent and the water content was
then calculated from the resulting reading.

Attenuated total-reflectance fouriertransform infrared spectroscopy
Attenuated total-reflectance Fourier-transform infrared
spectroscopy (ATR-FTIR) was performed using a Varian
7000e step-scan spectrometer (Agilent Technologies, Santa
Clara, CA). The powder was placed on the diamond ATR
crystal, covered with a glass coverslip, and held in place
with a specialized clamp. ATR crystal and IR spectra were
obtained at an 8 cm−1 spectral resolution between 700 and
4000 cm−1. The data were collected and analyzed using Varian
Resolutions software.

Hot-stage microscopy under
cross-polarizers
Using similar conditions previously reported by the authors,42
hot-stage microscopy (HSM) studies were completed using
a BX51 polarized microscope (Olympus, Tokyo, Japan)
equipped with an Instec STC200 heating unit and S302 hot
stage (Boulder, CO). The polarized light was filtered by a γ
530 nm U-TP530 filter lens. Powder samples were mounted
on a cover glass and heated from 25°C to 250°C at a heating
scan rate of 5°C/minute. The heating program was controlled
by WinTemp software, and images were digitally captured
via a SPOT Insight digital camera (Diagnostic Instruments,
Sterling Heights, MI).

Confocal Raman microscopy
and spectroscopy
Confocal Raman microspectroscopy (CRM) was performed
using an Aramis confocal dispersive Raman spectrometer
and fluorescence microscope system (Horiba Jobin Yvon,
Edison, NJ), using similar conditions previously reported by
the authors.43 The system is equipped with an Olympus BX41
confocal optical microscope and an Olympus U-LH 100 W
Hg lamp and U-RFL-T power source used for fluorescence
excitation and bright-field illumination. All optical images
and Raman spectra were obtained using a 50× objective.
Raman spectra and spectral maps were acquired using a
633 nm HeNe laser. Spectral maps were obtained with the
stage moved in increments of 2 µm. Each map point was
acquired using 2 seconds of detector exposure time, with
32 accumulations acquired per point using a grating of
600 grooves/mm and a center wavenumber of 1200 cm−1
(for spectra in the fingerprint region) and two accumulations
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acquired per point, with a grating of 950 grooves/mm and
a center wavenumber of 2900 cm−1 (for the C–H stretching
region). A confocal hole of 500 µm and a slit width of 100 µm
were used. Spectra covering the range of 200–4000 cm−1
were obtained in automatic scanning mode using the
950 groove/mm grating. Spectra were subjected to baseline
correction and smoothing prior to further analysis.

Aerosol dispersion performance analysis
by Next Generation Impactor™ (NGI™)
In accordance with the United States Pharmacopeia chapter 601 specifications on aerosols,44 the aerosol-dispersion
properties of the dry powder particles as DPIs were determined using the Next Generation Impactor™ (NGI™) with
a stainless steel induction port (ie, United States Pharmacopeia throat) attachment (model 170; MSP, Shoreview, MN),
equipped with specialized stainless steel NGI™ gravimetric
insert cups (MSP). The NGI™ was coupled with a Copley
TPK 2000 critical flow controller (Copley Scientific,
Nottingham, UK), which was connected to an HCP5 vacuum
pump (Copley Scientific). The airflow rate, Q, was measured
and adjusted prior to each experiment using a DFM 2000
flow meter (Copley Scientific).
The aerosolization studies were experimentally designed
by Design Expert® 8.0.7.1 software (Stat-Ease, Minneapolis,
MN). Glass-fiber filters (55 mm, type A/E; Pall Life Sciences,
Exton, PA) were placed in the stainless steel NGI™ gravimetric insert cups for NGI™ stages 1–7 to minimize bounce
or reentrapment.45 Three hydroxypropyl methylcellulose hard
capsules (size 3, Quali-V®; Qualicaps, Whitsett, NC) were
each loaded with 10 mg of powder and were then loaded into
a high-resistance (ie, high sheer stress) human DPI device,
the HandiHaler® (Boehringer Ingelheim, Ridgefield, CT), and
tightly inserted into the induction port. The NGI™ was run at
a controlled flow rate at Q = 60 L/minute with a delay time
of 10 seconds (NGI™ Flow controller) prior to the capsules
being needle-pierced open by the HandiHaler® mechanism,
where the particles were then drawn into the inertial impactor
for 10 seconds. This was done with a total of three capsules
per sample for a total of 30 mg total per run. For each 30 mg
run, the amount of particles deposited onto each stage was
determined gravimetrically by measuring the difference in
mass of the glass filters after particle deposition. For the
NGI™ Q = 60 L/minute, the effective cutoff diameters for
each impaction stage were calibrated by the manufacturer
and stated as: Stage 1 (8.06 µm); Stage 2 (4.46 µm); Stage 3
(2.82 µm); Stage 4 (1.66 µm); Stage 5 (0.94 µm); Stage 6
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(0.55 µm); and Stage 7 (0.34 µm). The fine particle dose
(FPD), fine particle fraction (FPF), respirable fraction (RF),
and emitted dose (ED) were calculated as follows:
FPD = mass of particles , 4.4 µm (stages 2–7)
FPF =
RF =

Fine particle dose
×100%
Initial particle mass loaded into capsules
Mass of particles < 4.4 µm (stages 2 through 7)
Total particle mass on all stages
× 100%

ED = [(initial mass in capsules - final mass remaining in capsules)
/initial mass in capsules] × 100%




The mass mean aerodynamic diameter (MMAD) and
geometric standard deviation (GSD) were determined using
a mathematical program written by Dr Warren Finlay. All
experiments were triplicated (n = 3).

Results
SEM, particle sizing, and size distribution
Formulated particle and surface morphologies were visualized and analyzed via SEM. Figures 2–5 include SEM

A

micrographs of the particles at 10,000× and corresponding
raw DPPC or DPPE-PEG at 1000×. Their corresponding
size (diameter), standard deviation, and range are exhibited
in Table 2, as determined using SigmaScan® software. 100
DPPC (pure one-component DPPC)-formulated particles
are smooth and spherical, and their diameter increased
with increasing pump rate (diameters of 0.642 ± 0.188,
0.790 ± 0.292, and 0.960 ± 0.499 µm for low P, medium P,
and high P, respectively). Formulated 95 DPPC:5 DPPEPEG2k particle size also increased with increasing pump
rate; however, only the high P formulation exhibited spherical morphology and a diameter of 1.166 ± 0.676 µm. Low P
and high P particle systems were rough and agglomerated,
and their diameter could not be determined. Similarly, 95
DPPC:5 DPPE-PEG3k and 95 DPPC:5 DPPE-PEG5k formulated particle sizes increased with increasing pump rate,
and the high P formulations were spherical with diameters
of 1.200 ± 0.931 µm and 1.161 ± 0.595 µm, respectively.
The low P and medium P formulations for both systems
were agglomerated and rough, and their diameters were not
determined. Also, the surface roughness of the high P particle
formulations seemed to be rough. This was a result of charging of the particles during SEM, as their initial morphology

B

WD 15.0 mm 10.0 kV x1.0 k

50 µm

C

WD 14.8 mm 5.0 kV x10k

5 µm

D

WD 15.3 mm 10.0 kV x10 k

5 µm

WD 14.9 mm 5.0 kV x10 k

5 µm

Figure 2 (A–D) Scanning electron micrographs of raw dipalmitoylphosphatidylcholine (DPPC) and spray-dried 100 DPPC particles at three pump rates. (A) Raw DPPC,
magnification 1000×; (B) DPPC particles at 10% (low P) pump rate, magnification 10,000×; (C) DPPC particles at 50% (medium P) pump rate, magnification 10,000×;
(D) DPPC particles at 100% (high P) pump rate, magnification 10,000×.
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A

B

WD 15.1 mm 10.0 kv x1.2 k

WD 13.3 mm 5.0 kv x10 k

25 µm

C

5 µm

D

WD 15.3 mm 10.0 kv x10 k

5 µm

WD 13.4 mm 5.0 kv x10 k

5 µm

Figure 3 (A–D) Scanning electron micrographs of raw dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-2k 95 DPPC:5 DPPE-PEG2k and co-spray-dried 95
dipalmitoylphosphatidylcholine (DPPC):5 DPPE-PEG 2k particles at three pump rates. (A) Raw DPPE-PEG2k, magnification 1000×; (B) 95 DPPC:5 DPPE-PEG2k particles at
10% (low P) pump rate, magnification 10,000×; (C) 95 DPPC:5 DPPE-PEG2k particles at 50% (medium P) pump rate, magnification 10,000×; (D) 95 DPPC:5 DPPE-PEG2k
particles at 100% (high P) pump rate, magnification 10,000×.

A

B

WD 15.1 mm 10.0 kv x1.2 k

25 µm

C

WD 15.2 mm 10.0 kv x10 k

5 µm

WD 15.3 mm 10.0 kv x10 k

5 µm

D

WD 15.1 mm 10.0 kv x10 k

5 µm

Figure 4 (A–D) Scanning electron micrographs of raw dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-3k (DPPE-PEG3k) and co-spray-dried 95
dipalmitoylphosphatidylcholine (DPPC):5 DPPE-PEG3k particles at three pump rates. (A) Raw DPPE-PEG3k, magnification 1000×; (B) 95 DPPC:5 DPPE-PEG3k particles at
10% (low P) pump rate, magnification 10,000×; (C) 95 DPPC:5 DPPE-PEG3k particles at 50% (medium P) pump rate, magnification 10,000×; (D) 95 DPPC:5 DPPE-PEG3k
particles at 100% (high P) pump rate, magnification 10,000×.
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A

B

WD 14.8 mm 10.0 kv x1.5 k

20 µm

C

WD 14.8 mm 10.0 kv x10 k

5 µm

WD 13.3 mm 5.0 kv x10 k

5 µm

D

WD 14.9 mm 5.0 kv x10 k

5 µm

Figure 5 (A–D) Scanning electron micrographs of raw dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-5k (DPPE-PEG5k) and co-spray-dried 95
dipalmitoylphosphatidylcholine (DPPC):5 DPPE-PEG 5k particles at three pump rates. (A) Raw DPPE-PEG5k, magnification 1000×; (B) 95 DPPC:5 DPPE-PEG 5k particles at
10% (low P) pump rate, magnification 10,000×; (C) 95 DPPC:5 DPPE-PEG 5k particles at 50% (medium P) pump rate, magnification 10,000×; (D) 95 DPPC:5 DPPE-PEG 5k
particles at 100% (high P) pump rate, magnification 10,000×.

prior to image capture was smooth and spherical. Overall, the
particle sizes exhibited by all formulated microparticulate/
nanoparticulate powders were in the respirable size range.

Powder X-ray diffraction
Powder X-ray diffractograms (Figure 6) showed the presence of a strong peak at 21° 2Θ for both raw DPPC and all
formulated 100 DPPC particles, which corresponds to the
presence of the lipid bilayer.37 Raw DPPE-PEG showed the
Table 2 Particle-size parameters of spray-dried DPPC and
co-spray-dried DPPC:DPPE-PEG particles (mean ± standard
deviation)
System

Diameter (μm)

Range (μm)

100 DPPC (low P)
100 DPPC (medium P)
100 DPPC (high P)
95 DPPC:5 DPPE-PEG2k (high P)
95 DPPC:5 DPPE-PEG3k (medium P)
95 DPPC:5 DPPE-PEG3k (high P)
95 DPPC:5 DPPE-PEG5k (medium P)
95 DPPC:5 DPPE-PEG5k (high P)

0.642 ± 0.188
0.790 ± 0.292
0.960 ± 0.499
1.166 ± 0.676
1.049 ± 0.529
1.200 ± 0.931
0.837 ± 0.299
1.161 ± 0.595

0.274–1.157
0.228–1.755
0.220–2.000
0.360–4.068
0.303–3.775
0.034–5.298
0.316–1.759
0.326–2.966

Abbreviations: DPPC, dipalmitoylphosphatidylcholine; DPPE, dipalmitoylphosphatidylethanolamine; PEG, poly(ethylene glycol).
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presence of strong peaks at 19° and 23° 2Θ, a small peak at
21° 2Θ, and smaller broad peaks above 25° 2Θ. The peaks
at 19°, 23°, and above 25° 2Θ are similar to previous results
for PEG powder,46 whereas the peak at 21° 2Θ corresponds
to the presence of a phospholipid bilayer. Upon spray-drying,
the peaks above 25° 2Θ disappeared, whereas the peaks at
19° and 23° 2Θ remained for all formulated particle systems.
Furthermore, the peak present at 21° 2Θ increased due to
the influence of DPPC in the particle formulation. Although
there was no correlation in peak intensity with spray-drying
pump rates, the intensity of the peaks corresponding to PEG
increased with increasing PEG chain length for the raw
DPPE-PEG compounds.

Differential scanning calorimetry
DSC thermograms for formulated particles and their corresponding raw counterparts can be seen in Figure 7. Raw DPPC
exhibited three endothermic peaks, including a crystal-to-gel
(Tc) bilayer phase transition at ∼47.1°C, pretransition peak
corresponding to a gel-to-ripple (Tp) phase at ∼67.0°C, and
the bilayer main phase transition (Tm) to the liquid crystalline phase at ∼72.0°C, where the hydrophobic acyl chain core
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Figure 6 Powder X-ray diffractograms of: (A) formulated spray-dried (SD) dipalmitoylphosphatidylcholine (DPPC) particles at three pump rates versus raw DPPC;
(B) formulated co-SD DPPC: dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-2k (DPPE-PEG2k) particles at three pump rates versus raw DPPC and raw DPPEPEG2k; (C) formulated co-SD DPPC:DPPE-PEG3k particles at three pump rates versus raw DPPC and raw DPPE-PEG3k; (D) formulated co-SD DPPC:DPPE-PEG5k particles
at three pump rates versus raw DPPC and raw DPPE-PEG5k.
Note: Low P, med P, and high P correspond to 10%, 50%, and 100% pump rates, respectively.

melted. This is consistent with our earlier findings on raw
DPPC powder.24 The phase behavior of solid-state DPPC, fully
hydrated DPPC, and at varying levels of water content in the
solid state have been previously reported by the authors.24–26
Formulated 100 DPPC particles exhibited the characteristic
bilayer main transition phase (Tm) at ∼68°C, which corresponds to the bilayer main transition phase of raw DPPC
confirming the presence of the phospholipid bilayer. The
bilayer phase temperatures for SD DPPC were slightly lower
than that of the raw DPPC, and it was determined that the heat
of fusion of the formulated particles increased with increasing pump rate (24.8, 29.2, and 36.1 J/g for low P, medium P,
and high P, respectively). Neither Tc nor Tp were observed in
the thermograms for the SD DPPC particles, indicating that
spray-drying rendered the bilayers in the gel state (not the
crystalline state, as was observed with raw DPPC). All DPPC
systems underwent decomposition around 160°C.
Raw DPPE-PEG2k exhibited two endothermic peaks,
including a pretransition peak at 43.5°C and main phase
transition at ∼52.1°C. The co-SD 95 DPPC:5 DPPE-PEG2k
particle systems exhibited two endothermic peaks: the
first around 47°C, which corresponds to the DPPE-PEG
main phase transition (Tc), and the second in the range
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of 70°C–75°C, which corresponds to the DPPC bilayer
main phase transition - Tm. Furthermore, the low P sample
exhibited a third endotherm near 90°C. Raw DPPE-PEG3k
exhibited a single endothermic peak at 52.0°C, corresponding
to the main phase transition. The 95 DPPC:5 DPPE-PEG3k
particles exhibited two endothermic peaks near 49.5°C
(corresponding to the DPPE-PEG3k transition phase) and
74°C (corresponding to the DPPC bilayer phase transition).
For the DPPC bilayer phase transition peaks, the heat of
fusion increased with increasing pump rate at 2.0, 10.7, and
17.0 J/g for low P, medium P, and high P, respectively. The
low P particles had a third endotherm near 100°C. Similarly,
raw DPPE-PEG5k exhibited a pretransition peak at 48.3°C
and main phase transition at 57.9°C. The 95 DPPC:5 DPPEPEG5k particles showed two endothermic peaks at 55.3°C
and 73°C, which corresponded to the main phase transition
of DPPE-PEG5k and DPPC, respectively. For the DPPC
bilayer phase transition peaks, the heat of fusion increased
with increasing pump rate at 2.6, 11.0, and 14.7 J/g for low P,
medium P, and high P, respectively. The low P particles had
a third endotherm near 100°C.
For the main phase transition temperatures corresponding
to the DPPE-PEG peaks (first endotherms for formulated
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Figure 7 Differential scanning calorimetry thermograms of: (A) formulated spray-dried (SD) dipalmitoylphosphatidylcholine (DPPC) particles at three pump rates versus
raw DPPC; (B) formulated co-SD DPPC:dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-2k (DPPE-PEG2k) particles at three pump rates versus raw DPPE-PEG2k;
(C) formulated co-SD DPPC:DPPE-PEG3k particles at three pump rates versus raw DPPE-PEG3k; (D) formulated co-SD DPPC:DPPE-PEG5k particles at three pump rates
versus raw DPPE-PEG5k.
Note: Low P, med P, and high P correspond to 10%, 50%, and 100% pump rates, respectively.

co-SD DPPC:DPPE-PEG particles), the temperature
increased with increasing PEG molecular weight. Also, the
peaks corresponding to DPPE-PEG in the formulated co-SD
powders are broader and result in high heats of fusion in
comparison to the DPPC-related peaks. Furthermore, all
formulated co-SD 95 DPPC:5 DPPE-PEG and raw DPPEPEG samples decomposed above 130°C.
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Karl Fischer coulometric titration
The residual water content in the solid state of the formulated
particles and their raw components are shown in Table 3.
The water content of raw DPPC was 1.74% ± 0.15% (w/w)
and ranged from 4.59% to 5.17% (w/w) for SD 100 DPPC
particles. The water content for raw DPPE-PEG2k was
0.70% ± 0.21% (w/w) and ranged from 1.29% to 3.13%
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Table 3 Water content of formulated spray-dried DPPC and cospray-dried DPPC:DPPE-PEG particles and their raw counterparts
analyzed via Karl Fischer coulometric titration (mean ± standard
deviation, n = 3)
System

Water% (w/w)

100 DPPC (low P)
100 DPPC (medium P)
100 DPPC (high P)
Raw DPPC
95 DPPC:5 DPPE-PEG2k (low P)
95 DPPC:5 DPPE-PEG2k (medium P)
95 DPPC:5 DPPE-PEG2k (high P)
Raw DPPE-PEG2k
95 DPPC:5 DPPE-PEG3k (low P)
95 DPPC:5 DPPE-PEG3k (medium P)
95 DPPC:5 DPPE-PEG3k (high P)
Raw DPPE-PEG3k
95 DPPC:5 DPPE-PEG5k (low P)
95 DPPC:5 DPPE-PEG5k (medium P)
95 DPPC:5 DPPE-PEG5k (high P)
Raw DPPE-PEG5k

4.93 ± 1.29
4.59 ± 1.03
5.17 ± 1.29
1.74 ± 0.15
1.29 ± 0.70
3.13 ± 1.17
1.76 ± 0.83
0.70 ± 0.21
2.43 ± 0.60
2.82 ± 0.89
4.34 ± 1.71
0.60 ± 0.12
1.46 ± 0.75
1.65 ± 0.26
3.11 ± 1.11
1.04 ± 0.65

Note: Low P, medium P, and high P correspond to 10%, 50%, and 100% pump rates,
respectively.
Abbreviations: DPPC, dipalmitoylphosphatidylcholine; DPPE, dipalmitoylphosphatidylethanolamine; PEG, poly(ethylene glycol).

(w/w) for formulated co-SD 95 DPPC:5 DPPE-PEG2k
particles. For raw DPPE-PEG3k, the water content was
0.60% ± 0.12% (w/w) and for formulated co-SD 95 DPPC:5
DPPE-PEG3k, particles ranged from 2.82% to 4.34%
(w/w). Finally, the water content for raw DPPE-PEG5k was
1.01% ± 0.65% (w/w), whereas it ranged from 1.46% to
3.11% (w/w) for the formulated co-SD 95 DPPC:5 DPPEPEG5k particles. There was no trend in the water-content
values for formulated systems based on the spray-drying
pump rates or type of DPPE-PEG used. All water-content
values were low and well within an acceptable range for
inhalable dry powder formulations.

Cross-polarizing light hot-stage microscopy
Representative micrographs of raw DPPE-PEG3k and
formul ated co-SD 95 DPPC:5 DPPE-PEG3k (high P)
particles are shown in Figures 8 and 9, respectively. Raw
DPPE-PEG3k showed dark agglomerates lacking birefringency between 25°C and 55°C, which indicated a noncrystalline, amorphous material. A phase transition was visualized
by HSM near 57°C to 58°C, which likely corresponded to
the gel to liquid-crystal transition, as shown in the DSC thermogam at 52°C for raw DPPE-PEG3k in Figure 7C. Melting
was visualized starting at 60°C by the formation of liquid
droplets, with decomposition occuring above 150°C.
The micrographs for co-SD 95 DPPC:5 DPPE-PEG3k
(high P) particles also showed dark agglomerates lacking
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birefringency between 25°C and 100°C, which indicated
a noncrystalline, amorphous material. No visible phase
transition was evident and melting started around 115°C,
as shown by liquid droplet formation. Decomposition was
evident above 185°C. This behavior corresponds closely to
that observed for raw DPPC (data not shown), which is the
primary component of these particles.

Attenuated total-reflectance fouriertransform infrared spectroscopy
Formulated particles and their raw counterparts underwent
ATR-FTIR analysis to determine the functional groups present in the systems, as shown in Figure 10. For both the raw
DPPC and SD 100 DPPC particles, the spectra indicated
the same characteristic peaks for all systems and were the
same as in previously reported literature.47 The spectra for
formulated co-SD 95 DPPC:5 DPPE-PEG particles, however,
exhibited peaks corresponding to DPPC and/or DPPE-PEG.
Interestingly, the characteristic peaks shown for raw DPPEPEG were the same as previously shown for pure PEG,48
showing the strong influence of the PEG presence in the
analysis of these systems. Although there is the absence of a
broad water peak (3200–3400 cm−1) for the raw DPPE-PEGs,
this peak was present in both the raw DPPC and SD 100
DPPC particles as well as the formulated co-SD 95 DPPC:5
DPPE-PEG particles. While certain peaks relating to characteristic functional groups relate to DPPC or DPPE-PEG only,
some are shared by both and have an influence on the formulated co-SD DPPC:DPPE-PEG particles. For instance, peaks
present in the formulated DPPC:DPPE-PEG particles that
are due to the influence of DPPC include those at 2924 cm−1
(–CH2 antisymmetrical stretching), 2852 cm−1 (–CH2 symmetrical stretching), 1250–1350 cm−1 (P=O stretching), and
721 cm−1 (–N+[CH3]3 symmetrical stretching). Peaks due to
the influence of DPPE-PEG (PEG) include 2870 cm−1 (–CH3
symmetrical stretching), 1342 cm−1 (alcohols), and 1276 cm−1
(ethers). Peaks in the formulated particles due to the influence of DPPC and/or DPPE-PEG (present in all three)
include 1720–1735 cm−1 (C–O ester stretching), 1465 cm−1
(–CH2 deformation, 1050–1150 cm−1 (–C–C–) and 960 cm−1
(–N+[CH3]3) antisymmetrical stretching).

Confocal Raman microscopy
and chemical imaging
Confocal Raman microscopy (CRM) and chemical imaging
was performed first on raw DPPC for comparison with formulated SD DPPC particles. The results are shown in Figure 11.
The full-range Raman spectra obtained via the microscope
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Figure 8 Representative hot-stage micrographs for raw dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-3k.
Note: Scale bar = 3 mm.

at several different points showed no difference between the
raw and SD DPPC, as seen in the selected spectra shown in
Figure 11A. Two 32 × 32 maps were made at regions of the
Raman spectrum centered at 2900 and 1200 cm−1. A representative map of the region between 1400 and 1520 cm−1 is
shown in Figure 11B and illustrates the observed results. The
intensity variation observed in the red map was minor and
showed no evidence of inhomogeneity within the particle.
The variation is likely caused by sample height effects and
minor density variations within the particle.
Raman microscopy and chemical imaging was also used
to assess the homogeneity of formulated co-SD 95 DPPC:5
DPPE-PEG2k (high P) particles. Bands were identified that
were specific for DPPC and DPPE-PEG2k, as shown in
Figure 12A. Two regions were selected that were specific
for DPPE-PEG2k, between 270 and 295 cm−1 and between
1225 and 1250 cm−1. For DPPC, a band at 700 and 740 cm−1

was chosen. The areas of these bands were extracted from a
32 × 32 Raman spectral map, and are shown in F
 igure 12B–D.
The blue, green, and red maps align with the bands denoted
by colored arrowheads in Figure 12A. The map intensity
observed for the selected bands, which are specific to the
two chemical components of the particle, is seen to correlate
between the three maps, indicating that DPPC and DPPEPEG2k are similarly distributed in the particle at the resolution limit of Raman microscopy. Variations in the band area
are caused by sample height effects and density variations
within the mapped particle. Formulated co-SD 95 DPPC:5
DPPE-PEG3k (high P) particles were examined in a similar
manner using the same set of Raman bands, leading to the
results shown in Figure 13. Again, the colored maps correlate
with each other and indicate that DPPC and DPPE-PEG3k
are distributed similarly. Formulated 95 DPPC:5 DPPEPEG5k (high P) particles were also examined using the
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175°C

185°C

200°C

250°C

Figure 9 Representative hot-stage micrographs for co-spray-dried 95 dipalmitoylphosphatidylcholine:5 dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-3k
(high P) particles.
Note: Scale bar = 3 mm.
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Figure 10 Attenuated total-reflectance Fourier-transform infrared spectra of: (A) formulated spray-dried (SD) dipalmitoylphosphatidylcholine (DPPC) particles at three
pump rates versus raw DPPC; (B) formulated co-SD DPPC:dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-2k (DPPE-PEG2k) particles at three pump rates versus
raw DPPC and raw DPPE-PEG2k; (C) formulated co-SD DPPC:DPPE-PEG3k particles at three pump rates versus raw DPPC and raw DPPE-PEG3k; (D) formulated co-SD
DPPC:DPPE-PEG5k particles at three pump rates versus raw DPPC and raw DPPE-PEG5k.
Note: Low P, med P, and high P correspond to 10%, 50%, and 100% pump rates, respectively.

same approach, as shown in Figure 14, and also indicated a
homogenous distribution of DPPC and DPPE-PEG5k.
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Figure 11 (A) Raman spectra obtained via confocal microscopy of raw
dipalmitoylphosphatidylcholine (DPPC) and formulated spray-dried (SD) DPPC at
100% pump rate. The colored arrowhead shows the mapped bands. (B) Raman
spectroscopic mapping showing the area of the Raman bands between 1400 and
1520 cm−1 (brighter-red colors indicate greater area) superimposed on a bright-field
optical image of the surface of a particle of formulated SD DPPC (100% pump rate).
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The aerosol properties of the formulated particles produced at
the highest pump rate (high P) were evaluated using an NGI
coupled with the HandiHaler® DPI device (FDA-approved).
The MMAD and geometric standard deviation values were
similar for all four systems that were analyzed, ranging between
4.0 and 4.5 µm and 2.1 and 2.7 µm, respectively. The fineparticle dose increased upon using PEGylated phospholipids
where SD 100 DPPC was 23.8% and co-SD 95 DPPC:5 DPPEPEG2k, 3k, and 5k were 29.4%, 30.2%, and 29.5%, respectively.
The ED was similar for all four systems, ranging from 91.2%
to 94.2%, whereas the RF% increased with increasing
PEGylation of the particles. These RF% values were 60.3% for
SD 100 DPPC and co-SD 95 DPPC:5 DPPE-PEG2k, 3k, and
5k were at 68.7%, 71.7% and 75.5%, respectively. Figure 15
demonstrates the actual aerosol dispersion performance of
the engineered dry powder microparticulate/nanoparticulate
aerosols showing the % deposition on each NGI™ stage.
Aerosol deposition on each NGI™ stage is measured, and in
particular deposition on the lower stages of stage 2 all the way
to stage 7 (lowest stage) is observed.
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Figure 12 (A) Raman spectra obtained via confocal microscopy of raw dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-2k (DPPE-PEG2k), formulated spray-dried
(SD) dipalmitoylphosphatidylcholine (DPPC), and formulated co-SD 95 DPPC:5 DPPE-PEG2k (high P). Colored arrowheads show mapped bands. (B) Raman spectroscopic
mapping showing the area of the Raman bands between 700 and 740 cm−1 (brighter colors indicate greater area) superimposed on a bright-field optical image of the surface
of a particle of formulated SD DPPC (100% pump rate). (C) Map showing the area of the Raman bands between 270 and 295 cm−1. (D) Map showing the area of the Raman
bands between 1225 and 1250 cm−1.

Discussion
This comprehensive and systematic study illustrates the
physicochemical properties of DPPC and DPPC:DPPE-PEG
microparticles and nanoparticles rationally designed for
the first time by an organic solution closed-mode advanced
spray-drying. Furthermore, this study also demonstrates for
the first time their aerosol dispersion performance as DPIs
for targeted pulmonary nanomedicine delivery, with excellent properties for high aerosol dispersion performance as
dry powder inhalation aerosols. A systematic experimental
design resulted in the successful design, development, and
optimization of twelve particle systems, which included pure
one-component SD DPPC particles and two-component
co-SD 95 mole% DPPC:5 mole% DPPE-PEG DPI particles
(using three different PEG chain lengths) at three different
pump rates. This study strived to elucidate the effects of the
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presence of DPPE-PEG, PEG chain length, and the effects
of the pump rate.
Overall, the use of dilute organic solution (such as
alcohols, which are considered “green” chemicals) imparts
a smaller primary droplet size by virtue of lower surface
tension in the range of 20–25 mN/m (in contrast to water,
which has a high surface tension of 72 mN/m and hence
produces larger primary droplets) with rationally designed
advanced spray-drying conditions resulted in the optimization
of particle characteristics necessary for effective dry powder
delivery. In addition, organic solution advanced spray-drying
in closed mode eliminates the need for water and minimizes
the residual water content in the final powder. This is an
important and novel aspect reported here, as minimizing
the residual water content in the solid state improves aerosol
dispersion performance and promotes solid-state stability.
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Figure 13 (A) Raman spectra obtained via confocal microscopy of raw dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-3k (DPPE-PEG3k), formulated spray-dried
(SD) dipalmitoylphosphatidylcholine (DPPC), and formulated co-SD 95 DPPC:5 DPPE-PEG3k (high P). Colored arrowheads show mapped bands. (B) Raman spectroscopic
mapping showing the area of the Raman bands between 700 and 740 cm−1 (brighter colors indicate greater area) superimposed on a bright-field optical image of the surface
of a particle of formulated SD DPPC (100% pump rate). (C) Map showing the area of the Raman bands between 270 and 295 cm−1. (D) Map showing the area of the Raman
bands between 1225 and 1250 cm−1.

SEM analysis showed that the particles exhibited an ideal size
range (0.5–1.5 µm), which is comparable to respirable trehalose dry powder particles in the 0.75–0.99 µm range made by
the novel process of organic solution advanced spray-drying
in closed-mode, as earlier reported by these authors.49 The
size and morphology of particles utilized in the inhalation
application is paramount in ensuring targeted delivery to
specific lung regions, since particles in the stated size range
are capable of delivering a payload to a specific lung region
(such as the deep lung).17,45,50–52 While all particles that had
measurable sizes were within an ideal size range, the morphology exhibited was not smooth and without agglomeration
for the entire set of particles. In particular, SD particles that
underwent the highest spray-drying rate of 30 mL/minute
(high P systems) had the best morphology, whereas the
low P and medium P systems were rough and agglomerated,
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which would limit the aerosolization and delivery of these
particles via inhalation methods. Overall, the highest pump
rate resulted in the most optimal particle set.
PXRD and DSC analysis showed that the organic solution advanced spray-drying in closed mode of dilute solutions with DPPC and/or DPPE-PEG resulted in particles
that demonstrated the presence of the lipid bilayer structure
(multilamellar) as evidence of the signature peaks for PXRD
and the characteristic bilayer phase-transition values of Tc, Tp,
and Tm, in DSC thermograms.24–26 PXRD data were the same
for both the raw and SD particles and proved the presence
of both the lipid bilayer(s) and PEG within the SD systems,
which were not affected by a change in pump rates. A relationship was seen between the intensity of the PXRD peaks
corresponding to PEG (at 19° and 23° 2θ) and the PEG chain
length, where the intensity increased with increasing PEG
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Figure 14 (A) Raman spectra obtained via confocal microscopy of raw dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-5k (DPPE-PEG5k), formulated spray-dried
(SD) dipalmitoylphosphatidylcholine (DPPC), and formulated co-SD 95 DPPC:5 DPPE-PEG5k (high P). Colored arrowheads show mapped bands. (B) Raman spectroscopic
mapping showing the area of the Raman bands between 700 and 740 cm−1 (brighter colors indicate greater area) superimposed on a bright-field optical image of the surface
of a particle of formulated SD DPPC (100% pump rate). (C) Map showing the area of the Raman bands between 270 and 295 cm−1. (D) Map showing the area of the Raman
bands between 1225 and 1250 cm−1.

chain length. DSC thermograms of pure SD DPPC particles
showed similar Tm values irrespective of spray-drying pump
rates, which corresponded to raw DPPC without a pretransition peak. This bilayer phase transition was also present in
co-SD DPPC:DPPE-PEG particles along with a secondary
endothermic peak, which corresponded to that of pure raw
DPPE-PEG, neither of which was dependent on the pump
rate. The relationship between the endothermic peak values
exhibited by the particles and the outlet temperatures from
the spray-drying process was likely a significant factor in
the successful formation of multilamellar particles using the
fastest pump rate. The outlet temperatures for the low and
medium pump rates (3 and 15 mL/minute, respectively) were
above the phase-transition temperatures of the formulated
PEGylated phospholipid particles, resulting in improper
formation and agglomeration. A higher pump rate decreased
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the outlet temperature, while allowing for the formation of
ideally sized, smooth particles that were not agglomerated
and properties suitable for inhalation aerosol delivery as
dry powders.
HSM enabled visualization as a function of temperature and confirmed the phase transitions of the raw DPPC
and DPPE-PEGs, as well as the formulated SD DPPC and
co-SD DPPC:DPPE-PEG SD particles. It also showed the
stability of the particles at physiological temperatures.
ATR-FTIR analysis on the SD particles in their dry state in
comparison to their raw components confirmed the presence
of both DPPC and DPPE-PEG where appropriate through
the signature peaks of each of these materials without the
destruction of particles that would occur using other FTIR
methods. Furthermore, organic spray-drying resulted in low
water content of the particles, which is necessary for effective
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Figure 15 Aerosol-dispersion performance as % deposition on each stage of the Next Generation Impactor at Q = 60 L/minute for: (A) 100 dipalmitoylphosphatidylcholine
(DPPC) (high P), (B) 95 DPPC:5 dipalmitoylphosphatidylethanolamine poly(ethylene glycol)-2k (DPPE-PEG2k) (high P), (C) 95 DPPC:5 DPPE-PEG3k (high P), and
(D) 95 DPPC:5 DPPE-PEG5k (high P).
Note: High P correspond to 100% pump rate.

particle delivery since residual water can have a significant
influence on impeding the dispersion of dry powder during aerosolization.53 These values were remarkably low for
inhalation applications, and this is another novel advantage
in organic solution spray-drying (ie, minimizes residual
water content in the final powder). Raman microscopy and
chemical imaging confirmed the chemical homogeneity of
the particles.
Excellent aerosol dispersion performance (Figure 15)
and optimal aerosol performance parameters (Table 4) were
demonstrated using the NGI™ coupled with the HandiHaler®
DPI device and clearly indicated that the formulated particles

would be optimal for efficient and predominant deposition
into the deep lung region for targeted delivery as inhaled
nanoparticles/microparticles as aerosolized powders. The
MMAD values were within the range (1–5 µm) necessary
for particles to deposit predominantly in the middle- to deeplung regions and deposit by sedimentation due to gravitational settling.1,7,8,52 For example, it was reported that porous
poly(lactic-co-glycolic) microparticles exhibited MMADs
ranging from 4.5 to 6.6 µm,5 whereas phospholipid/mannitol
SD particles ranged from 1.25 to 1.77 µm.37 Furthermore,
the ED, FPF, and RF values were all high compared to other
values reported in the literature.54,55 While not all of these

Table 4 Aerosol dispersion performance properties as aerosolized dry powders of PEGylated phospholipid particles including mass
median aerodynamic diameter (MMAD), geometric standard deviation (GSD), fine particle dose (FPD), fine particle fraction (FPF),
respirable fraction (RF), and emitted dose (ED) for inhalable microparticle/nanoparticle formulations all designed and produced at high P
(mean ± standard deviation, n = 3)
Aerosol system

100 DPPC

95 DPPC:5 DPPE-PEG2k

95 DPPC:5 DPPE-PEG3k

95 DPPC:5 DPPEPEG5k

MMAD (μm)
GSD (μm)
FPD (mg)
FPF (%)
RF (%)
ED (mg)
ED (%)

4.4 ± 0.9
2.7 ± 0.7
7.5 ± 1.5
23.8 ± 4.7
60.3 ± 8.5
28.7 ± 1.2
91.2 ± 4.0

4.5 ± 0.3
2.3 ± 0.0
9.1 ± 0.7
29.4 ± 2.8
68.7 ± 5.2
29.0 ± 0.9
93.1 ± 1.2

4.1 ± 0.2
2.2 ± 0.3
9.5 ± 1.1
30.2 ± 3.4
71.7 ± 3.0
29.6 ± 1.2
94.2 ± 2.6

4.0 ± 0.6
2.1 ± 0.2
9.0 ± 1.2
29.5 ± 4.3
75.5 ± 12.8
28.6 ± 0.9
93.2 ± 1.9

Abbreviations: DPPC, dipalmitoylphosphatidylcholine; DPPE, dipalmitoylphosphatidylethanolamine; PEG, poly(ethylene glycol).
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aerosol performance parameters are often reported, FPF%
values for porous poly(lactic-co-glycolic acid) particles were
reported to be in the range of 10.7%–33.8%5 and sodium alendronate from 34.4% to 62.0%.38 The novel findings reported
here indicate the significant potential of these lipopolymeric
lung surfactant-mimic particles to be utilized to effectively
deliver many different types of therapeutics to the lung as
inhaled dry powder nanomedicine aerosols.

Conclusion
This comprehensive and systematic study demonstrated
for the f irst time that inhalable DPPC:DPPE-PEG
microparticles and nanoparticles with differing PEG
lengths were rationally designed and successfully produced using the advanced organic spray-drying process
in closed mode for dilute alcohol solutions. The SD
lung surfactant-mimic phospholipid and lipopolymeric
particles produced from various rationally chosen pump
rates showed that the highest pump rate (30 mL/minute)
resulted in particles with smooth, spherical morphology
and optimal characteristics for inhalation aerosol delivery
as DPIs. This was a result of the lower outlet temperatures
exhibited, which was below the transition temperature
of these particles. Pharmaceutical processing conditions correlated in a meaningful manner with changes in
important physicochemical and particle properties, such
as morphology and transition temperatures, essential
for targeted pulmonary delivery as DPIs. These novel
particles as aerosolized dry powders of lung surfactantmimic and biocompatible lipopolymeric microparticles/
nanoparticles offer the potential to be used in the delivery
of a wide variety of pulmonary drugs, owing to their
inherent ability to encapsulate numerous types of drugs,
controlled drug release, enhanced mucus penetration by
phospholipid spreading and PEG penetration, and evasion
of phagocytosis by immune cells.
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